WO1995009005B1 - Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m - Google Patents
Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine mInfo
- Publication number
- WO1995009005B1 WO1995009005B1 PCT/US1994/010923 US9410923W WO9509005B1 WO 1995009005 B1 WO1995009005 B1 WO 1995009005B1 US 9410923 W US9410923 W US 9410923W WO 9509005 B1 WO9509005 B1 WO 9509005B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- oncostatin
- interleukin
- methods
- cytokine
- Prior art date
Links
- 102000004889 Interleukin-6 Human genes 0.000 title abstract 4
- 108090001005 Interleukin-6 Proteins 0.000 title abstract 4
- 229940100601 interleukin-6 Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 102000004140 Oncostatin M Human genes 0.000 claims abstract 9
- 108090000630 Oncostatin M Proteins 0.000 claims abstract 9
- 206010033661 Pancytopenia Diseases 0.000 claims abstract 6
- 208000024389 cytopenia Diseases 0.000 claims abstract 6
- 102000004127 Cytokines Human genes 0.000 claims abstract 5
- 108090000695 Cytokines Proteins 0.000 claims abstract 5
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims abstract 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims abstract 3
- 102000000646 Interleukin-3 Human genes 0.000 claims abstract 3
- 108010002386 Interleukin-3 Proteins 0.000 claims abstract 3
- 229940076264 interleukin-3 Drugs 0.000 claims abstract 3
- 208000007502 anemia Diseases 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 11
- 210000000130 stem cell Anatomy 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000036693 Thrombopoietin Human genes 0.000 abstract 1
- 108010041111 Thrombopoietin Proteins 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940047120 colony stimulating factors Drugs 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Abstract
La présente invention a pour objet des procédés d'utilisation de l'oncostatine-M (OM). Elle concerne en particulier l'utilisation d'OM pour stimuler la synthèse d'interleukine-6 (IL-6) dans des cellules cibles, en particulier des cellules endothéliales humaines. L'IL-6 ainsi produite peut exécuter diverses fonctions telles que la régulation de la croissance cellulaire, la différenciation des leucocytes et l'inhibition des tumeurs. La présente invention se rapporte en outre à l'utilisation de l'OM pour traiter les cytopénies, y compris l'anémie et la thrombocytopoïèse, et pour augmenter la tolérance aux rayonnements et aux médicaments cytotoxiques. Les procédés selon l'invention permettent donc des utilisations variées, notamment, mais non exclusivement, l'inhibition de la croissance tumorale, le traitement des cytopénies, et l'augmentation de la tolérance à la radiothérapie et à la chimiothérapie. L'OM peut être utilisée en association avec diverses cytokines, notamment l'érythropoïétine, les facteurs de stimulation de colonies, l'interleukine-3 ou la thrombopoïétine.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU78447/94A AU7844794A (en) | 1993-09-29 | 1994-09-27 | Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m |
| EP94929361A EP0721344A1 (fr) | 1993-09-29 | 1994-09-27 | Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m |
| JP7510413A JPH09505560A (ja) | 1993-09-29 | 1994-09-27 | オンコスタチンｍを用いるインターロイキン−６合成刺激方法および血小板産生誘発方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12923093A | 1993-09-29 | 1993-09-29 | |
| US08/312,205 | 1994-09-26 | ||
| US08/312,205 US5814307A (en) | 1989-04-10 | 1994-09-26 | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
| US129,230 | 1994-09-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1995009005A1 WO1995009005A1 (fr) | 1995-04-06 |
| WO1995009005B1 true WO1995009005B1 (fr) | 1995-05-04 |
Family
ID=26827388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/010923 WO1995009005A1 (fr) | 1993-09-29 | 1994-09-27 | Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5814307A (fr) |
| EP (1) | EP0721344A1 (fr) |
| JP (1) | JPH09505560A (fr) |
| AU (1) | AU7844794A (fr) |
| CA (1) | CA2172808A1 (fr) |
| WO (1) | WO1995009005A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000055319A1 (fr) * | 1999-03-12 | 2000-09-21 | Genentech, Inc. | Procedes et compositions pour inhiber la croissance des cellules neoplasiques |
| CZ298790B6 (cs) * | 1994-10-21 | 2008-01-30 | Kishimoto@Tadamitsu | Farmaceutický prípravek pro prevenci nebo lécení kachexie |
| CA2178256A1 (fr) * | 1995-06-06 | 1996-12-07 | Christopher H. Clegg | Hematopoiese induite par l'oncostatine m |
| WO1997016202A1 (fr) * | 1995-10-27 | 1997-05-09 | Amrad Operations Pty. Ltd. | Cytokines et leur utilisation dans le traitement et/ou la prophylaxie du cancer du sein |
| WO2001049715A2 (fr) * | 2000-01-06 | 2001-07-12 | Genentech, Inc. | Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique |
| WO2000053751A1 (fr) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Procedes et compositions pour l'inhibition de la croissance de cellules neoplasiques |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| PT1121439E (pt) * | 1998-10-13 | 2006-12-29 | Genentech Inc | Método e composições para inibir o crescimento de células neoplásticas |
| EP1135491A2 (fr) * | 1998-12-01 | 2001-09-26 | Genentech, Inc. | Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques |
| CA2450402A1 (fr) * | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Methodes et compositions permettant d'inhiber la croissance de cellules cancereuses avec la pro224 |
| ATE353339T1 (de) * | 1998-12-22 | 2007-02-15 | Genentech Inc | Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums |
| EP1867719A3 (fr) * | 1999-06-02 | 2008-03-19 | Genentech, Inc. | Procédés et compositions d'inhibition de la croissance de cellules néoplasiques |
| AU3246100A (en) * | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| AU2215300A (en) * | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| DK1185648T3 (da) * | 1999-06-02 | 2007-07-30 | Genentech Inc | Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst |
| IL160960A0 (en) * | 2001-09-24 | 2004-08-31 | Tosk Inc | Reduced toxicity cisplatin formulations and methods for using the same |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| WO2007149328A1 (fr) * | 2006-06-20 | 2007-12-27 | Genzyme Corporation | Milieux asériques et utilisations pour l'expansion de chondrocytes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6463395A (en) * | 1987-05-04 | 1989-03-09 | Oncogen | Oncostatin m and novel composition having antitumor activity |
| IL112767A (en) * | 1989-04-10 | 1998-01-04 | Oncogen | Pharmaceutical compositions containing oncostatin m |
| US5202116A (en) * | 1989-04-10 | 1993-04-13 | Oncogen | Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m |
| US5744442A (en) * | 1992-08-26 | 1998-04-28 | Bristol Meyers Squibb Company | Regulation of cellular invasiveness |
| US5460810A (en) * | 1992-09-02 | 1995-10-24 | Genetics Institute, Inc. | Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11 |
-
1994
- 1994-09-26 US US08/312,205 patent/US5814307A/en not_active Expired - Lifetime
- 1994-09-27 EP EP94929361A patent/EP0721344A1/fr not_active Withdrawn
- 1994-09-27 JP JP7510413A patent/JPH09505560A/ja active Pending
- 1994-09-27 WO PCT/US1994/010923 patent/WO1995009005A1/fr not_active Application Discontinuation
- 1994-09-27 CA CA002172808A patent/CA2172808A1/fr not_active Abandoned
- 1994-09-27 AU AU78447/94A patent/AU7844794A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1995009005B1 (fr) | Procede de stimulation de la synthese de l'interleukine-6 et d'induction de la thrombocytopoiese a l'aide d'oncostatine m | |
| Niitsu et al. | Expression of TGF-beta gene in adult T cell leukemia | |
| Uckun et al. | In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice | |
| JP2004525957A5 (fr) | ||
| Ogawa | Effects of hemopoietic growth factors on stem cells in vitro | |
| ATE71662T1 (de) | Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung. | |
| Baatout | Interleukin-6 and megakaryocytopoiesis: an update | |
| DE3771509D1 (de) | Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. | |
| Hamblin | Lymphokines and interleukins | |
| EP0325471A1 (fr) | Procédé pour supprimer la croissance de cellules normales et cancéreuses | |
| Crown et al. | Interleukin-1: biological effects in human hematopoiesis | |
| ES2036530T3 (es) | Utilizacion de un factor estimulante de las colonias granulociticas humano para preparar una composicion farmaceutica para el tratamiento de la leucemia mielogena. | |
| Slørdal et al. | Radioprotection by murine and human tumor‐necrosis factor: Dose‐dependent effects on hematopoiesis in the mouse | |
| Ishizuka et al. | Low molecular weight immunomodulators produced by microorganisms | |
| Maury | Anaemia in rheumatoid arthritis: role of cytokines | |
| Obradovich et al. | Effect of Recombinant Canine Granulocyte Colony‐stimulating Factor on Peripheral Blood Neutrophil Counts in Normal Cats | |
| Ogilvie | Hematopoietic growth factors: frontiers for cure | |
| Veldhuis et al. | Potential use of recombinant human interleukin-6 in clinical oncology | |
| RU2647833C1 (ru) | Гемостимулирующее средство | |
| Misawa et al. | Effects of macrophage colony-stimulating factor and interleukin-2 administration on NK1. 1+ cells in mice | |
| KAWATSU et al. | Effect of conagenin on thrombocytopenia induced by antitumor agents in mice | |
| Tefferi et al. | Current perspective in agnogenic myeloid metaplasia | |
| Smith | Use of hematopoietic growth factors for treatment of aplastic anemia | |
| Haan et al. | Microenvironmentally dependent effects on murine haemopoiesis by a prolonged interleukin‐1 treatment | |
| Hauke et al. | Hematopoietic growth factors |